Sulodexide Improves Contraction and Decreases Matrix Metalloproteinase-2 and -9 in Veins under Prolonged Stretch.
High pressure in the lower limb veins is often associated with chronic venous insufficiency (CVI) and varicose veins (VVs), making it important to search for the mechanisms and agents that control venous function. We have shown that protracted increases in venous stretch/wall tension reduce vein contraction and augment matrix metalloproteinase (MMP) -2 and -9. Also, MMP-2 and MMP-9 promote venodilation, a hallmark of VVs. Sulodexide (SDX) is a blend of glycosaminoglycans with efficient pro-fibrinolysis and anti-thrombosis activities, but its actions on vein function and the mechanisms involved are unclear. We tested the hypothesis that SDX enhances venous contractile response by decreasing MMP expression/activity in veins subjected to protracted stretch. Rat inferior vena cava (IVC) rings were treated with SDX (0.001-1mg/ml) or vehicle, equilibrated under control 0.5g-resting tension or protracted 2g-stretch for 18h, and the contractile response to 96mM-KCl and phenylephrine (Phe) in SDX-treated and non-treated veins was recorded. In IVC rings under control 0.5g-resting tension, SDX caused dose-dependent contraction, 96mM-KCl caused marked contraction (176mg/mg tissue), and Phe caused dose-dependent contraction with a maximum (56mg/mg tissue) at 10M. In IVC subjected to protracted 2g-stretch, 96mM-KCl-induced contraction was reduced to 112mg/mg and maximal Phe-induced contraction was decreased to 23mg/mg. In IVC subjected to protracted 2g-stretch plus SDX, 96mM-KCl-induced contraction was restored to 228mg/mg and maximal Phe-induced contraction was improved to 115mg/mg. Gelatin zymography and Western blots revealed increases in MMP-2 and MMP-9 levels/gelatinolytic activity in veins subjected to protracted 2g-stretch, and reversal to control levels in veins subjected to 2g-stretch plus SDX. Thus, SDX improves vein function and augments the contractile response in veins subjected to protracted stretch. The SDX-induced improvement of contraction and restoration of vein function appear to involve decreases in MMP-2 and MMP-9 and may contribute to the benefits of SDX in CVI and VVs.